Business Context and Reporting Period
This Form 8-K filing by Collegium Pharmaceutical, Inc. (COLL) reports on corporate governance changes. The report date is September 30, 2021, covering events occurring on September 24, 2021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure: Dr. Alison Fleming resigned as Executive Vice President and Chief Technical Officer, effective September 30, 2021.
- Appointment: Scott Sudduth, previously Vice President of Supply Chain since 2018, was promoted to succeed Dr. Fleming as Executive Vice President, Technical Operations, effective October 1, 2021.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to expressing appreciation for Dr. Fleming's service and confirming the transition of leadership in technical operations.
Investor Verification Checklist
- Verify the effective dates of Dr. Fleming's resignation and Mr. Sudduth's promotion.
- Confirm the new reporting structure for Technical Operations under Mr. Sudduth.
- Review subsequent filings for any impact on the company's drug development pipeline or operational strategy resulting from this leadership change.